Sotorasib demonstrates potential for KRAS-mutated pancreatic cancer

The KRAS G12C inhibitor sotorasib has shown “promising anticancer activity” in a phase 1/2 trial of patients with heavily pretreated, metastatic pancreatic cancer harbouring the target mutation, researchers report in The New England Journal of Medicine.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
CT brain cancer risk quantified for children and young adults

The European EPI-CT study has confirmed there is a linear dose–response relationship between radiation exposure during computed tomography imaging and the risk of malignant brain tumours, in children and young adults.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Antibody testing may identify cancer patients at increased risk of COVID-19 breakthrough infections

A Canadian population-based study has confirmed that people with cancer have an increased risk of breakthrough COVID-19 infection after vaccination, while UK research points to the feasibility of SARS-CoV-2 antibody testing to identify those with the lowest level of vaccine-derived protection.
First-line ribociclib plus ET RIGHT Choice for aggressive advanced breast cancer

Ribociclib plus endocrine therapy is associated with a significant progression-free survival benefit relative to combination chemotherapy in treatment-naïve patients with hormone receptor-positive, HER2-negative, advanced breast cancer with aggressive features, suggest trial data.
Minimal access breast surgery ‘valid’ option for early breast cancer

Minimal access breast surgery offers comparable long-term outcomes to conventional surgery for women with stage 0–III breast cancer, show the results of a propensity-matched, retrospective cohort study.
Meta-analysis reveals high risk for cutaneous AEs with PI3K inhibitors

The use of PI3K inhibitors for the treatment of cancer is associated with a high risk for developing cutaneous adverse events, suggests a meta-analysis published in JAMA Oncology.
High IL-6, CRP may predict increased frailty after breast cancer chemotherapy

Clinically fit older women with early breast cancer are more likely to experience chemotherapy-induced decline in frailty if they have high pretreatment levels of IL-6 and CRP, research shows.
Incidental sinoatrial node irradiation may increase AF risk in lung cancer

Incidental irradiation of the sinoatrial node during lung cancer chemoradiotherapy may be associated with an increased risk for atrial fibrillation and death, research suggests.
Extended anastrozole benefits dependent on tumor characteristics

Extending adjuvant aromatase inhibition to beyond 5 years of sequential therapy should not be recommended to all postmenopausal women with hormone receptor-positive early breast cancer, but some subgroups may benefit, research suggests.
Analysis points to FOLFIRINOX chemotherapy benefits for metastatic pancreatic cancer

FOLFIRINOX chemotherapy may offer better survival than gemcitabine plus nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma, suggests a comparative effectiveness study published in JAMA Network Open.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.